Beta Bionics (NASDAQ:BBNX) Raised to Hold at Baird R W

Beta Bionics (NASDAQ:BBNX) was upgraded by equities researchers at Baird R W to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

A number of other analysts have also issued reports on BBNX. LADENBURG THALM/SH SH began coverage on Beta Bionics in a research report on Thursday. They set a “neutral” rating and a $20.00 target price on the stock. Robert W. Baird assumed coverage on shares of Beta Bionics in a research note on Thursday. They issued a “neutral” rating and a $20.00 price target for the company.

Beta Bionics Price Performance

Shares of BBNX stock opened at $20.87 on Thursday. Beta Bionics has a fifty-two week low of $20.84 and a fifty-two week high of $24.50.

Insider Buying and Selling

In other news, insider Mike Mensinger bought 33,350 shares of the company’s stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, with a total value of $566,950.00. Following the transaction, the insider now directly owns 59,019 shares in the company, valued at approximately $1,003,323. This trade represents a 129.92 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the acquisition, the insider now directly owns 3,901,599 shares in the company, valued at $66,327,183. This represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.